Form 4: Ligand Pharmaceuticals Insider Buys Shares

Todd C. Davis, CEO and Director of Ligand Pharmaceuticals, acquired 132 shares of common stock through the Ligand Employee Stock Purchase Plan.

Summary

• Todd C. Davis, Chief Executive Officer and Director of Ligand Pharmaceuticals Inc., acquired 132 shares of common stock.
• The acquisition occurred on June 30, 2026, through the Ligand Employee Stock Purchase Plan.
• The purchase price was $160.7095 per share, totaling an investment of approximately $21,213.78.
• Following this transaction, Mr. Davis beneficially owns 199,513 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase by key management, signaling confidence.

Positives

• Insider purchase of shares by the CEO and Director, indicating confidence in the company's future.
• Acquisition made through an employee stock purchase plan, suggesting a commitment to long-term value.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider purchases, especially by senior management like CEOs and Directors, are often interpreted as a positive signal of their belief in the company's intrinsic value and future prospects within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders may view this insider purchase positively, interpreting it as a sign of management's confidence in the company's future performance.
• Employees participating in the Ligand Employee Stock Purchase Plan are aligned with management's investment in the company.

Key Dates

Recommendation

The acquisition of shares by the CEO and Director through an employee stock purchase plan is a positive signal of confidence. However, as a Form 4 filing detailing a routine transaction, it does not provide sufficient new strategic or financial information to warrant a strong buy or sell recommendation. A 'hold' reflects the neutral-to-positive sentiment derived from insider confidence without significant new catalysts.

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Stock Purchase Plan, CEO, Director, Common Stock